

# Needle Exchange Technology (NEXT): A novel internet-based mail- delivered syringe services program

BENJAMIN T HAYES, MD, MSW, MPH

JAMIE FAVARO, EXECUTIVE DIRECTOR, NEXT DISTRO

OCTOBER 7, 2020



**NEXT Distro**  
STAY ALIVE, STAY SAFE.



**Montefiore**



# Conflicts of interest


- Benjamin Hayes has no conflicts of interest to declare.
- Jamie Favaro is Executive Director of NEXT; no other conflicts to declare.

# Background

- Most people in the US have poor access to syringe services programs (SSPs)
  - > Rural areas have far fewer SSPs than urban areas<sup>1</sup>
  - > Women and young people are often underrepresented in SSP programs
  - > Stigma, fear of legal consequences and geography act as major barriers to in-person SSPs <sup>2, 3, 4, 5, 6, 7</sup>



93% of the 220 counties most vulnerable to HIV or HCV outbreaks are without SSP <sup>8,9</sup>



[opioid.amfar.org](http://opioid.amfar.org)

**amfAR**  
MAKING AIDS HISTORY

# NEXT DISTRO & NEXT NALOXONE

- NEXT DISTRO (began distributing 2018)
  - sterile injection equipment and other harm reduction supplies
- NEXT NALOXONE
  - naloxone for overdose prevention
- Goal: augment existing SSPs by
  1. Supporting people not otherwise accessing in-person SSPs
  2. Helping local services expand their reach
- Internet-based technology → mail distribution
- Encrypted messaging service (confidentiality)
- First formal program in US

# How does it work:

 **NEXT Distro**  
STAY ALIVE, STAY SAFE.

ABOUT GET NEXT **DONATE**   

WHAT IS  
**NEXT DISTRO?**

An online and mail-based harm reduction platform designed to reduce opioid overdose death, prevent injection-related disease transmission, and improve the lives of people who use drugs.

 ENG >

# Getting Sterile Injection Equipment:



## People Who Use Drugs

Access harm reduction supplies.

GET SUPPLIES



## Overdose First Responders

Are you most likely to be a first responder during an overdose?


GET NALOXONE



## Harm Reduction Collaborators

Interested in collaborating with NEXT?

COLLABORATE



## Health Departments + Rural Health Offices

We'll help you bring NEXT to your community.

GET NEXT



## General Public

Volunteer or donate to support our work.

GET INVOLVED

# Getting Harm Reduction Supplies:





NY NEXT

CA NEXT

NV NEXT

OTHER STATES











# Getting Naloxone:

REVERSING AN OPIOID OVERDOSE IS

# IN YOUR HANDS

[Get Naloxone](#)

[Report Naloxone Use](#)



ALABAMA

ALASKA

ARIZONA

ARKANSAS

CALIFORNIA

COLORADO

CONNECTICUT

DELAWARE

FLORIDA

GEORGIA

HAWAI'I

IDAHO

ILLINOIS

INDIANA

IOWA

KANSAS

KENTUCKY

LOUISIANA

MAINE

MARYLAND

MASSACHUSETTS

MICHIGAN

MINNESOTA

MISSISSIPPI

MISSOURI

MONTANA

NEBRASKA

NEVADA

NEW HAMPSHIRE

NEW JERSEY

NEW MEXICO

NEW YORK

NORTH CAROLINA

NORTH DAKOTA

OHIO

OKLAHOMA

OREGON

PENNSYLVANIA

• PHILADELPHIA

PUERTO RICO

RHODE

ISLAND

SOUTH

CAROLINA

SOUTH

DAKOTA

TENNESSEE

TEXAS

UTAH

VERMONT

VIRGINIA

WASHINGTON

WEST

VIRGINIA

WISCONSIN

WYOMING

ALABAMA

ALASKA

ARIZONA

ARKANSAS

CALIFORNIA

COLORADO

CONNECTICUT

DELAWARE

FLORIDA

GEORGIA

HAWAI'I

IDAHO

ILLINOIS

INDIANA

IOWA

KANSAS

KENTUCKY

LOUISIANA

MAINE

MARYLAND

MASSACHUSETTS

MICHIGAN

MINNESOTA

MISSISSIPPI

MISSOURI

MONTANA

NEBRASKA

NEVADA

NEW HAMPSHIRE

NEW JERSEY

NEW MEXICO

NEW YORK

NORTH CAROLINA

NORTH DAKOTA

OHIO

OKLAHOMA

OREGON

PENNSYLVANIA

• PHILADELPHIA

PUERTO RICO

RHODE

ISLAND

SOUTH

CAROLINA

SOUTH

DAKOTA

TENNESSEE

TEXAS

UTAH

VERMONT

VIRGINIA

WASHINGTON

WEST

VIRGINIA

WISCONSIN

WYOMING



RESOURCES IN

# North Carolina



In 2018, there were [1,783](#) opioid overdose deaths in the state of North Carolina.


If you are a person who uses drugs or if you are around people who use drugs, please consider learning how to respond to an opioid overdose and carrying naloxone (intranasal brand name: Narcan). Naloxone is a medication designed to reverse an opioid overdose. Opioids slow down the activity of the central nervous system. This can cause slowed or stopped breathing which may lead to death. Naloxone displaces the opioids from the opioid receptors in the brain which allows the person who is experiencing an opioid overdose to begin breathing normally. We have a [helpful FAQ](#) and are constantly updating it with questions from our site visitors. If you don't find what you're looking for, [let us know](#).



Naloxone Finder



Good Samaritan  
Policy



Crisis Support



Syringe Access



Pharmacy



Organizing

# GET NALOXONE MAILED TO YOU

If you need naloxone and **cannot access it locally**, you may qualify to have intramuscular naloxone mailed to you.

[Get Naloxone](#)





U.S. Postage  
\$3.30  
FIRST CLASS  
PERMIT NO. 100  
NEW YORK, NY  
NO POSTAGE  
NECESSARY  
IF MAILED  
IN THE  
UNITED STATES

Thank you for  
becoming a Travel  
service in-patient  
with correct me



**Give NARCAN® Nasal Spray from**

**3** Call for emergency help, medical help, Evaluate, and Support

**1** Gently insert the tip of the nozzle into either nostril. **2** Push the dose of NARCAN® Nasal Spray into the nostril. **3** Repeat the dose of NARCAN® Nasal Spray into the other nostril.

**4** Peel back the tab with the nozzle to open the NARCAN® Nasal Spray

**5** Hold the NARCAN® Nasal Spray with your thumb and index finger. Push the nozzle into the nostril.


**6** Press the plunger firmly to give the dose of NARCAN® Nasal Spray.

**7** Watch the person closely. If the person does not respond, or if the person starts to breathe on their own, call 911 for further medical help. The NARCAN® Nasal Spray is not a substitute for medical attention. If you are not sure how to use the NARCAN® Nasal Spray, call 1-800-451-6229 for more information.

**8** Repeat the dose of NARCAN® Nasal Spray if the person does not respond to the first dose. If you are not sure how to use the NARCAN® Nasal Spray, call 1-800-451-6229 for more information.

**9** If the person does not respond to the first dose, call 911 for further medical help. The NARCAN® Nasal Spray is not a substitute for medical attention. If you are not sure how to use the NARCAN® Nasal Spray, call 1-800-451-6229 for more information.

**10** If the person does not respond to the first dose, call 911 for further medical help. The NARCAN® Nasal Spray is not a substitute for medical attention. If you are not sure how to use the NARCAN® Nasal Spray, call 1-800-451-6229 for more information.



**STAY ALIVE**  
**STAY SAFE**

Life saving supplies delivered to your door





# Evaluation

## NEXT DISTRO: sterile injection supplies program

- Who does the program serve?

### Methods:

- Participants: newly requesting supplies 2/18 – 8/19
- Data collection: self-report – enrollment form from website
- Measures: sociodemographic info, self-reported overdose, HCV infection, previous source of supplies

# Results


Participant characteristics	N = 173 (%)
Mean age	35 yrs (20 – 64 yrs); 50% <33 yrs
White	87%
Latinx	6%
Black or African American	1.7%
Other	5.2%
Female	53%
Unstable housing or homeless	41%
Uninsured	59%



# Results

Drugs used past 30 days:	
Heroin	69%
Methamphetamine	51%
Opioid analgesics	34%
Overdoses, past 12 months	25%
Witnessed overdose in past 12 months	66%
HCV infection, self-report	38%
	50% of women
Distributing supplies to other people	63% (19 missing)

# Previous Sources of Injection Supplies



# Discussion

- High frequency of overdose and HCV infection
- Few participants previously used pharmacies or SSPs for supplies
- NEXT reaches large proportion of women and young adults, which are often under-represented in traditional SSPs

# Next steps

- Research:
  - Evaluate NEXT's data on services to underserved populations
  - Evaluate NEXT Naloxone services
- NEXT service delivery:
  - Building their own encrypted web application
    - Other SSPs will be able to use this app to expand their services
  - Evolve the website into an open-access, multi-language hub for drug user resources
  - Expand to offer more telehealth services

# Acknowledgements

- Thank you to NEXT for their collaboration.
- Thank you to Dr. Aaron D. Fox for his mentorship and to Dr Czarina Behrends for her insights and suggestions.



# References

1. Jarlais, D. C. D., Nugent, A., Solberg, A., Feelemyer, J., Mermin, J., & Holtzman, D. (2015). Syringe service programs for persons who inject drugs in urban, suburban, and rural areas—United States, 2013. *Morbidity and mortality weekly report*, 64(48), 1337-1341.
2. Rivera AV, DeCuir J, Crawford ND, Amesty S, Lewis CF. Internalized stigma and sterile syringe use among people who inject drugs in New York City, 2010-2012. *Drug Alcohol Depend*. Nov 1 2014;144:259-64. doi:10.1016/j.drugalcdep.2014.09.778
3. Beletsky L, Heller D, Jenness SM, Neaigus A, Gelpi-Acosta C, Hagan H. Syringe access, syringe sharing, and police encounters among people who inject drugs in New York City: a community-level perspective. *Int J Drug Policy*. Jan 2014;25(1):105-11. doi:10.1016/j.drugpo.2013.06.005
4. Cloud, D. H., Ibragimov, U., Prood, N., Young, A. M., & Cooper, H. L. (2019). Rural risk environments for hepatitis c among young adults in appalachian kentucky. *International Journal of Drug Policy*, 72, 47-54.
5. Delany-Moretlwe, S., Cowan, F. M., Busza, J., Bolton-Moore, C., Kelley, K., & Fairlie, L. (2015). Providing comprehensive health services for young key populations: needs, barriers and gaps. *Journal of the International AIDS Society*, 18, 19833.
6. El-Bassel, N., & Strathdee, S. A. (2015). Women who use or inject drugs: an action agenda for women-specific, multilevel and combination HIV prevention and research. *Journal of acquired immune deficiency syndromes (1999)*, 69(Suppl 2), S182.
7. Canary, L., Hariri, S., Campbell, C., Young, R., Whitcomb, J., Kaufman, H., & Vellozzi, C. (2017). Geographic disparities in access to syringe services programs among young persons with hepatitis C virus infection in the United States. *Clinical Infectious Diseases*, 65(3), 514-517.
8. amFAR. (2017, November 3). Syringe Services Programs and the Opioid Epidemic. Retrieved August 26, 2020, from <https://www.amfar.org/ssp-opioid-epidemic/>
9. Van Handel MM, Rose CE, Hallisey EJ, et. al. County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States. *J Acquir Immune Defic Syndr*. 2016 Nov 1;73(3): 323-331 <https://www.cdc.gov/pwid/vulnerable-counties-data.html>